Industry Strength Score
18/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
PROFOUND MEDICAL CORP (PROF) Stock Price & Overview
NASDAQ:PROF • CA74319B5027
Current stock price
6.86 USD
+0.16 (+2.39%)
At close:
6.73 USD
-0.13 (-1.9%)
After Hours:
The current stock price of PROF is 6.86 USD. Today PROF is up by 2.39%. In the past month the price increased by 6.69%. In the past year, price increased by 31.17%.
PROF Key Statistics
52-Week Range3.76 - 8.95
Current PROF stock price positioned within its 52-week range.
1-Month Range5.84 - 7.23
Current PROF stock price positioned within its 1-month range.
- Market Cap
- 249.292M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.41
- Dividend Yield
- N/A
PROF Stock Performance
Today
+2.39%
1 Week
-1.86%
1 Month
+6.69%
3 Months
-8.53%
Longer-term
6 Months +13.01%
1 Year +31.17%
2 Years -6.92%
3 Years -43.07%
5 Years -61.18%
10 Years N/A
PROF Stock Chart
PROF Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to PROF. When comparing the yearly performance of all stocks, PROF turns out to be only a medium performer in the overall market: it outperformed 61% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
PROF Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PROF. The financial health of PROF is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PROF Earnings
On March 5, 2026 PROF reported an EPS of -0.27 and a revenue of 5.98M. The company missed EPS expectations (-0.25% surprise) and missed revenue expectations (-18.19% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateMar 5, 2026
PeriodQ4 / 2025
EPS Reported-$0.27
Revenue Reported5.977M
EPS Surprise -0.25%
Revenue Surprise -18.19%
PROF Forecast & Estimates
5 analysts have analysed PROF and the average price target is 8.59 USD. This implies a price increase of 25.16% is expected in the next year compared to the current price of 6.86.
For the next year, analysts expect an EPS growth of 36.49% and a revenue growth 79.69% for PROF
Analysts
Analysts80
Price Target8.59 (25.22%)
EPS Next Y36.49%
Revenue Next Year79.69%
PROF Financial Highlights
Over the last trailing twelve months PROF reported a non-GAAP Earnings per Share(EPS) of -1.41. The EPS decreased by -25.89% compared to the year before.
Income Statements
Revenue(TTM)16.10M
Net Income(TTM)-42.57M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.95% | ||
| ROE | -64.08% | ||
| Debt/Equity | 0.07 |
Chartmill High Growth Momentum
EPS Q2Q%-35%
Sales Q2Q%43.09%
EPS 1Y (TTM)-25.89%
Revenue 1Y (TTM)44.36%
PROF Ownership
Ownership
Inst Owners45.42%
Shares36.34M
Float34.87M
Ins Owners4%
Short Float %6%
Short Ratio9.52
PROF Industry Overview
PROF operates in the Health Care Equipment sub-industry within the Health Care sector. This group contains 12 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
25/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
35%
Outperformed 35% of sub-industries
3 Month Rank
27%
Outperformed 27% of sub-industries
6 Month Rank
24%
Outperformed 24% of sub-industries
Industry Fundamentals & Breadth
- Members
- 12
- New Highs
- 16.7%
- New Lows
- 16.7%
- Average ROE
- %
- Average Profit Margin
- %
- Average Operating Margin
- %
- Average P/E
- Average Fwd P/E
- Average Debt/Equity
- 0.1
PROF Competitors/Peers
The largest stocks on the US markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | 39.25 | 162.59B | ||
| ABT | ABBOTT LABORATORIES | 14.24 | 155.452B | ||
| SYK | STRYKER CORP | 17.41 | 112.876B | ||
| BSX | BOSTON SCIENTIFIC CORP | 14.31 | 83.969B | ||
| EW | EDWARDS LIFESCIENCES CORP | 24.9 | 48.418B | ||
| IDXX | IDEXX LABORATORIES INC | 38.32 | 45.068B | ||
| BDX | BECTON DICKINSON AND CO | 10.94 | 42.515B | ||
| RMD | RESMED INC | 16.7 | 29.867B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 10.74 | 27.847B | ||
| DXCM | DEXCOM INC | 20.18 | 23.611B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 9.11 | 16.047B | ||
| PEN | PENUMBRA INC | 63.83 | 12.792B | ||
| GMED | GLOBUS MEDICAL INC - A | 20.03 | 12.354B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PROF
Company Profile
Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Company Info
IPO: 2014-09-24
PROFOUND MEDICAL CORP
2400 Skymark Ave Unit 6
Mississauga ONTARIO L4W 5K5 CA
CEO: Arun Menawat
Employees: 131
Phone: 16474761350
PROFOUND MEDICAL CORP / PROF FAQ
What does PROF do?
Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Can you provide the latest stock price for PROFOUND MEDICAL CORP?
The current stock price of PROF is 6.86 USD. The price increased by 2.39% in the last trading session.
Does PROFOUND MEDICAL CORP pay dividends?
PROF does not pay a dividend.
How is the ChartMill rating for PROFOUND MEDICAL CORP?
PROF has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists PROF stock?
PROF stock is listed on the Nasdaq exchange.
What is the analyst forecast for PROF stock?
5 analysts have analysed PROF and the average price target is 8.59 USD. This implies a price increase of 25.16% is expected in the next year compared to the current price of 6.86.
Can you provide the market cap for PROFOUND MEDICAL CORP?
PROFOUND MEDICAL CORP (PROF) has a market capitalization of 249.29M USD. This makes PROF a Micro Cap stock.